Faron Pharmaceuticals Oy Faron to Present at H.C. Wainwright
January 04 2021 - 1:00AM
RNS Non-Regulatory
TIDMFARN
Faron Pharmaceuticals Oy
04 January 2021
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Faron to Present at H.C. Wainwright BioConnect
TURKU - FINLAND, January 4, 2021 - Faron Pharmaceuticals Ltd ( "
Faron") (LON: FARN), the clinical stage biopharmaceutical company ,
today announced that Dr. Markku Jalkanen, Chief Executive Officer
of Faron Pharmaceuticals, will present in a pre-recorded
presentation at the virtual H.C. Wainwright BioConnect Conference
that will be available on-demand starting Monday, January 11, 2021
at 6:00 a.m. ET.
An audio webcast of the presentations will be available in the
"Investors" section on Faron's website at
https://www.faron.com/investors
ENDS
For more information please contact:
Stern Investor Relations, Inc.
Julie Seidel, Naina Zaman
Phone: +(1)212 362 1200
Email: faron@sternir.com
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs. The Company currently has
a pipeline based on the receptors involved in regulation of immune
response in oncology and organ damage. Clevegen (bexmarilimab), its
investigative precision immunotherapy, is a novel anti-Clever-1
antibody with the ability to switch immune suppression to immune
activation in various conditions, with potential across oncology,
infectious disease and vaccine development. Currently in phase I/II
clinical development as a novel macrophage checkpoint immunotherapy
for patients with untreatable solid tumours, Clevegen has potential
as a single-agent therapy or in combination with other standard
treatments including immune checkpoint molecules. Traumakine, the
Company's pipeline candidate to prevent vascular leakage and organ
failures is currently being tested in several Phase III studies
around the world against COVID-19. Traumakine is intravenous IFN
beta-1a, which is a strong anti-viral and anti-inflammatory agent.
Faron is based in Turku, Finland. Further information is available
at www.faron.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKKDBNDBDDFBN
(END) Dow Jones Newswires
January 04, 2021 02:00 ET (07:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2023 to Apr 2024
